Benjamin William Caulier

My research project is focused on the development of an innovative anti-cancer modality, the Chimeric Antigen Receptor (CAR) therapy. This approach harnesses the potential of patients’ own immune cells to specifically kill their cancer. Practically, patients’ lymphocytes are modified with an innovative receptor (the CAR) to be redirected against a tumor antigen. The main goal of my project is to identify novel “targetable” antigens and develop innovative CAR designs to address the impediments of current CAR therapy especially against solid tumors.